Back to EZorb Newsletter Index





In this issue:


1. Share Success: Letters From Readers
2. Research News: Optimal Central BP Thresholds Proposed
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?

1. Share Success: Letters From Readers 


Letter I: From John C.

Received at Testimonial Submit Form on Monday, June 17, 2013 at 01:08:25



When I read about the cordyceps study on line, I decided to try Marvlix at a time when I was due to have blood lab work done.

April 14th I started taking 8 caps a day and lab work was done on April 30th, my test results changed from a creatinine level of 2.5 to 1.5.

Since that time my blood was tested again and there was an improvement to 1.4 with a egfr of 50. At my currant age 69 and starting with a creatinine level of 2.5 and a egfr of 26 I can hardly believe what's happened. I would be very interested in your opinion.

I should add that I was in stage 5 kidney failure March 4,2011 after open heart surgery and improved to 2.5 creatinine level with a egfr of 26 stage 4 for little over two years.

Letter II: From Frank

Received at Testimonial Submit Form on Thursday, March 14, 2013 at 20:32:15



Hello!! I took ezorb for some time and it renewed all my bone. Now I don't have any pain. EZorb is for real. Thanks thanks for this wonderful product!

PS- do you ship to Campinas (Brazil)? In the event you do what's shipping cost? Thanks for kindly assistance.


Letter III: From Barbara


Received at Testimonial Submit Form on Thursday, January 17, 2013 at 13:57:49



Hi, my name is Barbara. Several years ago, I experienced bone spurs in both of my feet. As I am into herbs, I researched my books about bone spurs and found that calcium aspartate anhydrous to be the best remedy. So I called around to local pharmarcies and to my shop where I get my usual herbs. Nothing pure that I could find, so I googled the name and sure enough Ezorb from Elixir Industry came up.

I read one testimonial about bone spurs and immediately ordered. I WAS CURED--NO MORE BONE SPURS. I didn't follow through taking Ezorb; however, a few years later I was hit by a car and my right femur was busted up. My Orthopedic doctor stated I healed quickly which I contribute partly to my past Ezorb consumption.

In 2010, I fractured my left fibula and had to wear a boot for several weeks, so I ordered more Ezorb. But once again I did not continue it.

In August 2012, I started having lower back pain. The pain would come and go but in December became unbearable. For the short of it, after three visits to the medical field, one prescription of Percocet and Nabumetone, and still no relieve, I remembered my previous experiences with Ezorb.

A new supply is on its way to my house right now and I know for sure that I will never let my supply of Ezorb ever lapse again. I am so excited and cannot wait for the elimination of my continued upset stomach and am POSITIVELY sure that I will have more relieve with Ezorb--THANKS!!!

-BJP, Colorado Springs CO, January 2013


From the Desk of EZorb Newsletter Editor:

This newsletter is now read by over 70,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.

2. Research News: Optimal Central BP Thresholds Proposed


Central blood pressure (CBP) edges closer to clinical use with the establishment of a threshold predictive for cardiovascular mortality.

The results of an observational study of more than 3000 Taiwanese people indicate that 130/90 mmHg may be the optimal CBP cutoff for hypertension, with normotension at pressures below 110/80 mmHg.

"Physiologically, with its close proximity to vital organs and the better prognostic value, CBP should be the most relevant BP relating to vascular events," say lead researcher Chen-Huan Chen (Taipei Veterans General Hospital, Taiwan) and team in the Journal of the American College of Cardiology.

"Cuff BP is not so much a surrogate, but a compromised measure that is recorded because of technical limitations."

The derivation cohort comprised 1272 people, aged an average of 52 years, who were free of overt cardiovascular disease. Their average cuff systolic BP was 11.6 mmHg higher than their average CBP, which was measured by a validated noninvasive method.

The researchers obtained their proposed CBP thresholds from the derivation cohort by calculating the CBP equivalents to standard cuff BP thresholds and examining their association with cardiovascular mortality over a median 15 years of follow up.

In a validation cohort of 2501 people, aged an average of 54 years and with a median 10 years of follow up, prehypertension (systolic CBP 110–129 mmHg) was associated with a nonsignificantly increased risk for cardiovascular mortality, relative to normotension (systolic CBP LT 110 mmHg). And hypertension (GT 130 mmHg) was associated with significant risk increases of 2.14-fold for total mortality, 3.08-fold for cardiovascular mortality, and 6.12-fold for stroke mortality.

Each 10 mmHg increase in systolic CBP significantly raised the risk for all these outcomes, whereas cuff systolic BP was only associated with total and stroke mortality.

In an editorial accompanying the study, Michael Weber (State University of New York, USA) and Raymond Townsend (University of Pennsylvania, Philadelphia, USA) note that the exclusion of patients with overt cardiovascular disease "is acceptable in describing the natural history of BP values but not necessarily relevant to patients in clinical practice."

They also observe that risk thresholds for nonfatal vascular events could be different, and stress that only intervention trials can prove the benefits of treating to any CBP target.

"Even so," they say, "we believe we are now at a point where central BP should emerge not only as a key endpoint in research studies but as a measurement of growing interest and value to clinicians."

Original research was published in J Am Coll Cardiol 2013; Advance online publication.

3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now



4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ for a copy of the instructions.



5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index

  Copyright 2013 Elixir Industry